Your browser doesn't support javascript.
loading
Lazarevic-Lasègue sign / Sinal de Lazarevic-Lasègue
Maranhão-Filho, Péricles; Vincent, Maurice.
  • Maranhão-Filho, Péricles; Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Departamento de Clínica Médica. Rio de Janeiro. BR
  • Vincent, Maurice; Eli Lilly and Company. Indianapolis. US
Arq. neuropsiquiatr ; 76(6): 421-423, June 2018. graf
Article in English | LILACS | ID: biblio-950549
ABSTRACT
ABSTRACT Charles Lasègue is reputed to have described the test/sign bearing his name, but he never wrote about it and misinterpreted its mechanism. The purpose of this note is to highlight the work of the Serbian, Laza Lazarević, who was first to present the original report of this seminal sign in sciatica and provide its appropriate pathophysiological interpretation.
RESUMO
RESUMO Charles Lasègue guarda a reputação de ter descrito o sinal que leva seu nome, mas nunca escreveu sobre isso e interpretava erradamente sua etiopatogenia. O propósito desta nota é chamar atenção para o trabalho do sérvio Laza Lazarević, que apresentou a descrição original do sinal mais importante na ciatalgia e forneceu a interpretação apropriada da sua fisiopatologia.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Sciatica / Diagnostic Techniques, Neurological Type of study: Diagnostic study Country/Region as subject: Europa Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2018 Type: Article Affiliation country: Brazil / United States Institution/Affiliation country: Eli Lilly and Company/US / Universidade Federal do Rio de Janeiro/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Sciatica / Diagnostic Techniques, Neurological Type of study: Diagnostic study Country/Region as subject: Europa Language: English Journal: Arq. neuropsiquiatr Journal subject: Neurology / Psychiatry Year: 2018 Type: Article Affiliation country: Brazil / United States Institution/Affiliation country: Eli Lilly and Company/US / Universidade Federal do Rio de Janeiro/BR